SuperworthAytu Biopharma profit margin AYTU
Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.
- Net margin, 12 months
- −24.8%
- Operating margin, 12 months
- −14.4%
- Net margin on a year earlier
- −4.3 pts
- Peer median
- 9.2%
Over the twelve months to Jun 30, 2026, Aytu Biopharma kept −24.8% of its revenue as net profit, with an operating margin of −14.4% and a gross margin of 64.0%.
Five years earlier its net margin was −88.8%.
The median for 3 large drugmakers of a similar size is 9.2%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2026 | −24.8% | −14.4% | 64.0% |
| FY2025 | −20.4% | −11.8% | 69.0% |
| FY2024 | −24.3% | −2.4% | 75.3% |
| FY2023 | −15.9% | −15.9% | 62.0% |
| FY2022 | n/a | n/a | 54.1% |
| FY2021 | −88.8% | −89.7% | 44.5% |
| FY2020 | −49.3% | −76.5% | 72.7% |
| FY2019 | n/a | n/a | 69.9% |
| FY2018 | n/a | n/a | 44.0% |
| FY2017 | n/a | n/a | 56.0% |
| FY2016 | n/a | n/a | 62.6% |
| FY2015 | n/a | n/a | 66.3% |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q4 FY26 | −24.8% | −4.3 pts | −14.4% | |
| Q3 FY26 | −60.2% | −62.7 pts | −26.8% | |
| Q2 FY26 | −39.0% | −30.5 pts | −13.9% | |
| Q1 FY26 | −20.5% | −10.7 pts | −13.2% | |
| Q4 FY25 | −20.4% | +3.9 pts | −11.8% | |
| Q3 FY25 | 2.5% | +19.3 pts | −3.8% | |
| Q2 FY25 | −8.5% | +11.5 pts | −10.6% | |
| Q1 FY25 | −9.8% | +15.3 pts | −2.6% | |
| Q4 FY24 | −24.3% | −8.4 pts | −2.4% | |
| Q3 FY24 | −16.8% | +12.6 pts | 1.0% | |
| Q2 FY24 | −20.0% | +52.7 pts | −6.8% | |
| Q1 FY24 | −25.1% | +54.6 pts | −16.5% |
Against its peers
Companies in Drug Manufacturers - General nearest Aytu Biopharma's size, closest first, today.
| Company | Profit margin |
|---|---|
| AYTUAytu Biopharma | −24.8% |
| ATNMActinium Pharmaceuticals | n/m |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| Peer median | 9.2% |
Where Aytu Biopharma ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Aytu Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.